Last reviewed · How we verify
LMWH in fixed intermediate dose
At a glance
| Generic name | LMWH in fixed intermediate dose |
|---|---|
| Sponsor | Anders Perner |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Intensive Care Platform Trial (PHASE4)
- TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy (PHASE4)
- Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |